These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37662409)

  • 1. Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma.
    Augustin RC; Newman S; Li A; Joy M; Lyons M; Pham M; Lucas PC; Smith K; Sander C; Isett B; Davar D; Najjar YG; Zarour HM; Kirkwood JM; Luke JJ; Bao R
    bioRxiv; 2023 Aug; ():. PubMed ID: 37662409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma.
    Augustin RC; Newman S; Li A; Joy M; Lyons M; Pham MP; Lucas P; Smith K; Sander C; Isett B; Davar D; Najjar YG; Zarour HM; Kirkwood JM; Luke JJ; Bao R
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37857525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer.
    Sammons S; Elliott A; Barroso-Sousa R; Chumsri S; Tan AR; Sledge GW; Tolaney SM; Torres ETR
    Front Oncol; 2023; 13():1235902. PubMed ID: 37637072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types.
    Bao R; Stapor D; Luke JJ
    Genome Med; 2020 Oct; 12(1):90. PubMed ID: 33106165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers.
    Luke JJ; Bao R; Sweis RF; Spranger S; Gajewski TF
    Clin Cancer Res; 2019 May; 25(10):3074-3083. PubMed ID: 30635339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures.
    Hossain SM; Gimenez G; Stockwell PA; Tsai P; Print CG; Rys J; Cybulska-Stopa B; Ratajska M; Harazin-Lechowska A; Almomani S; Jackson C; Chatterjee A; Eccles MR
    Front Immunol; 2022; 13():955063. PubMed ID: 36248850
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Liu J; Lin J; Wang X; Zheng X; Gao X; Huang Y; Chen G; Xiong J; Lan B; Chen C; Si L; Chen Y
    Front Immunol; 2022; 13():725679. PubMed ID: 35844619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumoral CD73: An immune checkpoint shaping an inhibitory tumor microenvironment and implicating poor prognosis in Chinese melanoma cohorts.
    Gao Z; Wang L; Song Z; Ren M; Yang Y; Li J; Shen K; Li Y; Ding Y; Yang Y; Zhou Y; Wei C; Gu J
    Front Immunol; 2022; 13():954039. PubMed ID: 36131912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: A multiplex immunohistochemistry-based single-cell analysis.
    Isomoto K; Haratani K; Tsujikawa T; Makutani Y; Kawakami H; Takeda M; Yonesaka K; Tanaka K; Iwasa T; Hayashi H; Ito A; Nishio K; Nakagawa K
    Lung Cancer; 2022 Dec; 174():71-82. PubMed ID: 36347190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor cell p38 inhibition to overcome immunotherapy resistance.
    Luke JJ; Dadey RE; Augustin RC; Newman S; Singh KB; Doerfler R; Behr S; Lee P; Isett B; Deitrick C; Li A; Joy M; Reeder C; Smith K; Urban J; Sellitto L; Jelinek M; Christner SM; Beumer JH; Villaruz LC; Kulkarni A; Davar D; Poklepovic AS; Najjar Y; Zandberg DP; Soloff AC; Bruno TC; Vujanović L; Skinner HD; Ferris RL; Bao R
    Res Sq; 2023 Aug; ():. PubMed ID: 37645831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma.
    Bao R; Spranger S; Hernandez K; Zha Y; Pytel P; Luke JJ; Gajewski TF; Volchenboum SL; Cohn SL; Desai AV
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34272305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.
    Gajewski TF; Corrales L; Williams J; Horton B; Sivan A; Spranger S
    Adv Exp Med Biol; 2017; 1036():19-31. PubMed ID: 29275462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping the single-cell landscape of acral melanoma and analysis of the molecular regulatory network of the tumor microenvironments.
    He Z; Xin Z; Yang Q; Wang C; Li M; Rao W; Du Z; Bai J; Guo Z; Ruan X; Zhang Z; Fang X; Zhao H
    Elife; 2022 Jul; 11():. PubMed ID: 35894206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment.
    Pizzolla A; Keam SP; Vergara IA; Caramia F; Thio N; Wang M; Kocovski N; Tantalo D; Jabbari J; Au-Yeung G; Sandhu S; Gyorki DE; Weppler A; Perdicchio M; McArthur GA; Papenfuss AT; Neeson PJ
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35550554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of genetic aberrations and tumor immune microenvironment in primary acral melanoma.
    Huang R; Shen G; Ren Y; Zheng K; Wang J; Shi Y; Yin JC; Qin L; Zhang G; Zhao M; Su X; Li L; Wang F; Shao Y; Liu B; Zou Z
    J Transl Med; 2023 Feb; 21(1):78. PubMed ID: 36739402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 9-Gene Signature Correlated With CD8
    Yan K; Lu Y; Yan Z; Wang Y
    Front Immunol; 2021; 12():622563. PubMed ID: 34220795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of fatty acid metabolism-related molecular subtype biomarkers and their correlation with immune checkpoints in cutaneous melanoma.
    Xu Y; Chen Y; Jiang W; Yin X; Chen D; Chi Y; Wang Y; Zhang J; Zhang Q; Han Y
    Front Immunol; 2022; 13():967277. PubMed ID: 36466837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ferroptosis-related lncRNA signature predicts prognosis and immunotherapy efficacy in cutaneous melanoma.
    Xu Y; Chen Y; Niu Z; Yang Z; Xing J; Yin X; Guo L; Zhang Q; Yang Y; Han Y
    Front Surg; 2022; 9():860806. PubMed ID: 35937602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic Cell Vaccination in Metastatic Melanoma Turns "Non-T Cell Inflamed" Into "T-Cell Inflamed" Tumors.
    Bulgarelli J; Tazzari M; Granato AM; Ridolfi L; Maiocchi S; de Rosa F; Petrini M; Pancisi E; Gentili G; Vergani B; Piccinini F; Carbonaro A; Leone BE; Foschi G; Ancarani V; Framarini M; Guidoboni M
    Front Immunol; 2019; 10():2353. PubMed ID: 31649669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment.
    Kawashima S; Inozume T; Kawazu M; Ueno T; Nagasaki J; Tanji E; Honobe A; Ohnuma T; Kawamura T; Umeda Y; Nakamura Y; Kawasaki T; Kiniwa Y; Yamasaki O; Fukushima S; Ikehara Y; Mano H; Suzuki Y; Nishikawa H; Matsue H; Togashi Y
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.